Quantum ($QNTM) Drug Approval Delay and Communication Missteps

1:25-cv-10565

Case number

01/06/2021

Class period Start

10/15/2025

Class period End

02/23/2026

Lead Plaintiff motion deadline

$QNTM investors filed a claim against Quantum for allegedly misleading investors about the regulatory timeline and approval expectations for its lead drug candidate, ensifentrine, intended for COPD treatment.
After revealing that the FDA had extended the review period and would not approve the drug by the original PDUFA date, $QNTM dropped 56% from $21.54 on June 25, 2024, to $9.48 on June 26, 2024.
$QNTM investors can join this case to be notified about potential recovery.
Case Details:

Between October 28, 2023, and June 26, 2024, Quantum publicly stated that it was on track to receive FDA approval for ensifentrine by June 26, 2024, its original PDUFA date. Executives repeatedly confirmed in earnings calls and investor presentations that the company had not been notified of any delays, and that they had no reason to believe the FDA would not meet the expected timeline.

However, Quantum allegedly failed to disclose that the FDA had requested additional information about the drug’s manufacturing, triggering a three-month extension to the review period. Instead of informing investors promptly, the company maintained its original approval timeline in public statements.

On June 25, 2024, just one day before the expected approval, Quantum disclosed that the FDA would not be able to complete the review on time and had extended the PDUFA date by three months to September 26, 2024. The next day, $QNTM stock collapsed by 56%, closing at $9.48, down from $21.54 on the prior day.

Based on these events, $QNTM investors filed a claim against Quantum, alleging the company:
It misled investors by reaffirming approval timelines while knowing about the FDA's request for additional information.
It failed to disclose material changes to the drug review process promptly.
It provided incomplete or misleading information about the regulatory status of its lead product.
Investors argue that Quantum misrepresented its interactions with the FDA and misled the market about the timing of ensifentrine’s approval, resulting in steep losses when the delay was revealed.

Case Type

US Securities Class Action

Case Status

Lead Plaintiff Appointment

Alleged Offence

Misleading Statements,

Financial Misrepresentation,

Failure to Disclose

Suspected Party

Directors,

Management

Security Type

Stocks

Trade Direction

Long

Shock Event Date

12/06/2023

Filing date

12/19/2025

Lead Plaintiff Deadline

02/23/2026

Trusted by industry leaders

Endorsed by top professionals who trust our innovative solutions to drive impactful results.